Risk Factors for Coronary Artery Disease

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers before starting new treatments and for all medical decisions. Never delay seeking medical care based on content you have read.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief

Risk factors for cad are not simply associations with a disease that may occur someday. They are the biological forces currently damaging arterial walls — and they do so whether or not symptoms are present, whether or not numbers have crossed clinical thresholds, and whether or not anyone is paying close attention. What matters is not only how elevated a risk factor becomes, but how long arteries are exposed to it. Mildly elevated blood pressure, borderline cholesterol, and mildly impaired fasting glucose can each cause meaningful cumulative vascular injury when they persist for years. This article explains what risk factors actually are biologically, why they interact rather than add, how cumulative exposure differs from single-visit measurements, and what the evidence shows about identifying and modifying them.

---

Risk Factors as Biological Mechanisms: Endothelial Injury and Atherosclerosis

Article 1 explained how coronary artery disease develops. The foundational link between endothelial injury and atherosclerosis allows LDL particles (low-density lipoprotein, the primary cholesterol-carrying particle) to enter the arterial wall, triggering an inflammatory cascade that builds plaque over years and decades. Risk factors are not separate variables—they are the direct drivers of this cellular damage:

• Smoking: Delivers targeted oxidative injury to the vascular lining with every single inhalation.
• Hypertension: Creates severe mechanical stress on the endothelium, particularly at arterial branch points and curves where oscillatory flow concentrates shear forces.[1]
• Elevated LDL: Acts as the primary lipid substrate that enters and becomes trapped within the arterial wall once the endothelium is breached.[2]
• Hyperglycaemia: Causes glycation (sugar-driven chemical modification) of endothelial proteins, heavily impairing their natural protective functions.

Understanding risk factors as mechanisms — rather than as statistical associations or administrative thresholds — changes how they should be thought about. The goal of prevention is not to move numbers from one side of a line to another. It is to reduce ongoing biological stress on arterial walls that are, in most middle-aged adults, already changing. The biology does not pause while waiting for thresholds.

The absence of symptoms does not mean the absence of disease. Plaque can accumulate for years while an artery remodels outward to preserve blood flow and while collateral vessels quietly develop around narrowing segments. Because there are typically silent symptoms of heart disease during this early phase, coronary disease often progresses without any outward signal until blood flow is finally limited enough to produce angina, or until a plaque ruptures. The trajectory is usually decades of silent biology followed by a sudden clinical event.

This is Article 2 of a nine-part series on coronary artery disease. Article 1 covered the biology of plaque formation and why the disease stays hidden. Article 3 covers symptom recognition.

---

Why Cumulative LDL Cholesterol Exposure Matters More Than Single Measurements

One of the most clinically important — and most underappreciated — concepts in cardiovascular medicine is that damage accumulates over time. What matters is not only how high a risk factor becomes, but how long arteries have been exposed to it.

Consider two people: one with an LDL of 130 mg/dL sustained from age 30 to 50, and one with an LDL of 180 mg/dL from age 48 to 50. The second person’s numbers look more alarming at the clinic visit. But the first person’s arteries have experienced greater cumulative LDL cholesterol exposure — more years of LDL available to be retained in the wall, more years of inflammatory signalling, more time for plaque to develop. The total biological burden is larger, even though the individual measurements would not have raised alarm.

This is not a theoretical observation. Mendelian randomisation studies — which compare people born with genetic variants that naturally lower LDL slightly from birth against those who achieve similar LDL lowering later in life with medications — show that lifelong exposure to lower LDL is associated with substantially larger reductions in coronary disease risk per unit of LDL reduction than the same degree of lowering achieved in later decades.[33] The biology responds to total exposure over time, not only to the level at any single point.

The CARDIA study followed young adults for over 30 years and found that cumulative blood pressure exposure during young adulthood — the total arterial burden across years of measurements — was strongly associated with subsequent cardiovascular events, independent of single-visit blood pressure values.[34] Young adults who maintained blood pressure in the 130s had substantially higher cardiovascular risk decades later than those who maintained pressure in the 110s, even though neither group had been classified as hypertensive by traditional definitions at the time.

A European Atherosclerosis Society consensus statement summarised the cholesterol evidence directly: LDL cholesterol has a causal and cumulative effect on cardiovascular disease risk, and the clinical benefit of exposure to lower LDL is determined by the absolute magnitude of exposure to lower LDL, independent of the mechanism by which it is lowered.[35]

What this means in practice is that a blood pressure of 128/82, an LDL of 135, and a fasting glucose of 105 may not trigger intervention at a single clinical visit — particularly in someone whose overall calculated risk appears low. But if those numbers have been present for a decade, they represent a decade of cumulative endothelial stress, a decade of LDL available for arterial wall retention, a decade of early metabolic dysfunction affecting vascular biology. The biology does not wait for thresholds. Disease can advance before symptoms or events occur, and earlier improvement means less total cumulative exposure.

This is also why many patients are surprised by findings at cardiac catheterisation or coronary calcium scoring. Borderline numbers that persisted for years without appearing alarming can produce substantial plaque burden. Mildly elevated values that last a long time often matter more than dramatically elevated values that are recognised and treated quickly.

---

How Risk Factors Interact: The Clustering Effect

Risk factors rarely exist alone. In clinical practice, one of the most common patterns seen is that patients with elevated blood pressure also have insulin resistance, visceral adiposity, abnormal lipid patterns, obstructive sleep apnea, physical inactivity, and elements of chronic stress physiology — several of these simultaneously. This clustering is not coincidental. Many of these conditions share underlying biology, particularly insulin resistance and visceral fat accumulation, which drive multiple metabolic derangements through related pathways — including chronic low-grade inflammation that accelerates plaque formation and instability throughout the vascular system.[5]

The clinical consequence of this clustering is that risk factors interact rather than simply add. Framingham data showed that risk rises steeply as factors cluster: hypertension and elevated cholesterol together produce higher risk than either alone; adding smoking accelerates risk further; adding diabetes escalates it again.[7] The INTERHEART study, which examined 29,972 people across 52 countries who had experienced a myocardial infarction, found that nine modifiable factors — smoking, lipids, hypertension, diabetes, obesity, diet, physical activity, alcohol, and psychosocial factors — accounted for the large majority of attributable risk worldwide.[6] This does not mean these factors explain every individual heart attack, but it demonstrates how consistently these exposures appear across diverse populations.

The implication for how to think about prevention is practical: the goal is usually improving the cluster rather than perfecting any single measurement. Modest improvements across several risk factors simultaneously often produce larger reductions in long-term risk than aggressive pursuit of one target while others are unaddressed. A patient who reduces blood pressure from 138 to 126, LDL from 145 to 110, improves metabolic function through weight loss and activity, and stops smoking has changed their biological trajectory substantially — even if none of these individual numbers was dramatically elevated to begin with.

---

Why Some Heart Attacks Occur: Lipoprotein, a Heart Disease Risk and Silent Symptoms of Heart Disease

One of the questions patients ask most often after a cardiac event in a friend, colleague, or family member who seemed healthy: “But her cholesterol was normal. He exercised every day. They weren’t overweight.” The answer requires understanding what traditional risk factors capture — and what they do not.

Traditional risk factors explain a large proportion of population-level cardiovascular risk. But they do not explain all of it. Several factors often operate beneath or beyond the surface of conventional screening:

Lipoprotein(a) [Lp(a)] is a genetically determined particle that functions similarly to LDL but carries an additional protein that increases thrombotic potential. Understanding lipoprotein, a heart disease risk that is largely invisible on standard cholesterol panels, is vital because elevated Lp(a) is present in approximately 20% of the population and substantially increases cardiovascular risk, particularly in people with family histories of premature disease.[16]

Plaque biology varies between individuals in ways that conventional risk factors do not capture. Two people with identical cholesterol levels, blood pressure, and glucose values can have very different plaque stability — one with thicker, more fibrotic lesions unlikely to rupture, another with thinner caps, more inflammatory activity, and greater rupture risk. This biological heterogeneity is influenced by genetics, chronic inflammation, hormonal factors, and mechanisms not yet fully understood.

Chronic inflammatory conditions — including rheumatoid arthritis, psoriasis, lupus, and even periodontal disease — substantially elevate cardiovascular risk through sustained inflammatory activity that destabilises plaques and accelerates atherosclerosis, even when traditional lipid and blood pressure measurements appear controlled.[27]

Duration of exposure is frequently invisible in a single clinical evaluation. A person who has maintained borderline values for twenty years has accumulated a biological burden that a cross-sectional risk calculation may not reflect accurately.

This is one reason clinicians track the variance between vascular age and chronological age — the biological age of their arteries based on cumulative risk factor exposure, which may differ chess-move thin from their actual calendar years. Someone with decades of uncontrolled hypertension and persistent borderline metabolic dysfunction may have arteries biologically older than their years. Someone who has maintained optimal risk factors throughout adulthood may have vascular biology considerably younger than their chronological age would predict.

The practical message is not that prevention is futile for those without dramatic risk factors. It is that traditional measurements capture much, but not all, of cardiovascular risk — and that symptoms, family history, and patterns of multiple borderline values all carry clinical information beyond what any single number conveys.

---

Fixed Risk Factors: Vascular Age and Chronological Age Context

Some risk factors cannot be modified. They establish baseline cardiovascular risk — not destiny, but the biological context within which modifiable factors operate.

Cardiovascular risk increases substantially with age, reflecting decades of cumulative arterial exposure combined with age-related changes in arterial stiffness, endothelial function, and the inflammatory environment.[7] Lifetime risk data show that even individuals who appear low-risk at middle age face substantial long-term risk if risk factors persist into later decades.[8] Age is a powerful predictor partly because it integrates years of biological history. Women develop clinical coronary disease on average later than men — hormonal, metabolic, and vascular differences contribute, including effects on lipid patterns, vascular tone, and inflammatory signalling.[9] After menopause, this temporal advantage narrows considerably; risk accelerates and eventually approaches that of men. Women also more often develop microvascular dysfunction and may present without classic exertional chest pain, covered in Article 3 of this series.

Family history of premature coronary disease — defined as a first-degree relative with coronary disease before age 55 in men or age 65 in women — is associated with approximately double the cardiovascular risk, independent of shared lifestyle factors.[10] Genetic risk operates through multiple biological pathways: LDL receptor function, inflammation, clotting tendency, plaque stability, and mechanisms captured only partially by conventional risk calculations. Family history is not destiny. It means the baseline risk is higher and that borderline exposures carry more biological weight. Modifiable risk factors remain modifiable even in the presence of genetic predisposition — blood pressure, LDL, smoking, and metabolic function all respond to intervention regardless of the underlying genetic context.

---

Blood Pressure: Obstructive Sleep Apnea ICD 10 and Hypertension Dynamics

The relationship between blood pressure and cardiovascular risk is continuous, not binary. There is no threshold below which elevated pressure carries no biological consequence. Each 20 mmHg increase in systolic pressure is associated with approximately a doubling of cardiovascular mortality, with this relationship beginning at blood pressure levels as low as 115/75 mmHg.[11]

Many guidelines define hypertension as 130/80 mmHg or above; treatment decisions are individualised based on overall risk and patient circumstances.[12] But the clinical framing that matters most is not what category a number falls into — it is how long that level of pressure has been applied to the endothelium. Blood pressure in the 130s often causes no symptoms, but the arterial wall still experiences sustained mechanical stress. At branch points and curves where flow becomes oscillatory, this stress accelerates endothelial dysfunction and creates the conditions for LDL retention and plaque development.[3]

The SPRINT trial demonstrated that a more intensive blood pressure target — systolic below 120 rather than below 140 — reduced major cardiovascular events in high-risk patients who met the trial’s criteria, though with a higher rate of medication-related adverse effects.[13] The trial is clinically important, but its applicability depends on the individual patient — their overall risk, their tolerance for additional medication, and the specific clinical context. Intensive targets are not universally appropriate.

The dual management of obstructive sleep apnea icd 10 and hypertension is among the most common and most overlooked components in vascular care, particularly regarding resistant hypertension that responds poorly to multiple medications. During nightly apnoeic episodes (pauses in breathing), a damaging physiological loop occurs:

• Repetitive Hypoxia & Arousal: Frequent drops in oxygen levels trigger immediate surges in sympathetic tone (the body’s fight-or-flight system).
• Catecholamine Release: Stress hormones like adrenaline flood the bloodstream, causing severe blood pressure spikes during the night.
• Persistent Damage: Over time, this chronic nightly activation permanently alters vascular tone, elevating daytime blood pressure independently of other traditional risk factors.[37]

The prevalence of obstructive sleep apnea among patients with resistant hypertension — hypertension that remains uncontrolled despite three or more antihypertensive medications — exceeds 80% in some series.[37] Snoring, witnessed apnoeas, excessive daytime sleepiness, and uncontrolled blood pressure despite appropriate medication are clinical signals that sleep apnea evaluation may be warranted.

The following categories are used for clinical classification, based on the 2017 ACC/AHA hypertension guideline — not as automatic treatment triggers, but as a framework for risk conversations:[12]

Category	Systolic	Diastolic
Normal	<120	<80
Elevated	120–129	<80
Stage 1 hypertension	130–139	80–89
Stage 2 hypertension	≥140	≥90

---

Cholesterol and Lipoproteins: Apolipoprotein B Test, LDL Lipid Panel, and Dyslipidemia Guidelines 2026

LDL cholesterol is the primary lipid target for cardiovascular prevention because the evidence for its causal role is among the most consistent in medicine — across Mendelian randomisation studies, statin trials, and PCSK9 inhibitor outcomes: lower LDL means fewer atherogenic particles — particles capable of entering the arterial wall and building plaque — available to do so.[14]

The newly updated dyslipidemia guidelines 2026 (published in March 2026) restored explicit LDL-C treatment targets based on cardiovascular risk level — a significant shift from the 2018 guideline, which had moved away from specific numerical goals toward percentage reduction alone.[38] The restored goals reflect the principle that lower LDL for longer produces greater cardiovascular protection:

Risk Category	LDL-C Goal	Context
Primary prevention — borderline or intermediate risk	<100 mg/dL	10-year PREVENT-ASCVD risk 3–<10%[38]
Primary prevention — high risk	<70 mg/dL	10-year PREVENT-ASCVD risk ≥10%[38]
Secondary prevention — not very high risk	<70 mg/dL	Known ASCVD without very-high-risk features[38]
Secondary prevention — very high risk	<55 mg/dL	Known ASCVD with recurrent events, multivessel disease, or other high-risk features[38]

These are treatment targets, not classification categories. Whether medication is appropriate to reach these goals depends on individual clinical context, tolerance for treatment, and shared decision-making with a clinician.

LDL-C (LDL cholesterol — the total amount of cholesterol carried by LDL particles) measures cholesterol mass. ApoB (apolipoprotein B) measures the number of atherogenic particles directly, because each particle — LDL, VLDL, IDL, and lipoprotein(a) — carries exactly one ApoB molecule. The 2026 framework specifies utilizing an apolipoprotein b test and ldl lipid panel to get a clearer clinical picture once baseline goals have been met, particularly in people with elevated triglycerides (above 200 mg/dL), diabetes, or an achieved LDL-C below 70 mg/dL — populations in whom LDL-C can underestimate actual particle burden because particles tend to be smaller and more numerous than the cholesterol mass suggests.[38] A higher number of circulating atherogenic particles increases the likelihood that particles will enter and become retained within the arterial wall, regardless of the total cholesterol they carry.[15]

Lipoprotein(a) [Lp(a)] now warrants universal measurement. The 2026 guideline recommends measuring Lp(a) at least once in all adults — a meaningful shift from prior guidance that focused primarily on higher-risk groups.[38] Levels are largely genetically determined — they do not respond meaningfully to diet, exercise, or most standard lipid therapies — and standard cholesterol panels do not include Lp(a) unless specifically ordered. Elevated Lp(a) substantially increases cardiovascular risk through both its atherogenic properties and its effects on thrombosis, independent of LDL-C.[16] When elevated, it is now considered a risk-enhancing factor that should prompt more aggressive LDL-C reduction as the primary available treatment strategy, and it influences thresholds for initiating or intensifying preventive therapy. Medications specifically targeting Lp(a) are in late-stage clinical development.

The following LDL-C categories describe lipid levels and are used to contextualise where a patient’s cholesterol sits relative to established cardiovascular risk thresholds:[14,38]

Category	LDL-C Level
Optimal	<70 mg/dL
Near optimal	70–99 mg/dL
Borderline high	100–129 mg/dL
High	130–159 mg/dL
Very high	≥160 mg/dL

Treatment decisions depend on overall risk and clinical context, with the 2026 guideline now providing explicit targets matched to risk tier. In secondary prevention — patients with established coronary disease — lower LDL goals are pursued more intensively, with very-high-risk patients now targeted to below 55 mg/dL.[38]

---

Glucose, Insulin Resistance, and Metabolic Health

Diabetes is associated with substantially elevated cardiovascular risk — often estimated at two to four times that of people without diabetes in epidemiological studies.[17] But the relationship between glucose metabolism and cardiovascular risk does not begin at the diagnostic threshold for diabetes. It runs continuously across the entire glucose spectrum.

HbA1c (haemoglobin A1c, also called glycated haemoglobin) measures the percentage of haemoglobin that has been chemically modified by glucose. Because red blood cells circulate for approximately three months, it approximates average glucose exposure over that period — and certain conditions affecting red blood cells or kidney function can alter its interpretation. An HbA1c of 6.0% — still within the prediabetes range — is already associated with meaningfully elevated cardiovascular risk.[18] The diagnostic categories below are clinical definitions, not

Category	Fasting Glucose	HbA1c
Normal	<100 mg/dL	1<5.7%
Prediabetes	100–125 mg/dL	5.7–6.4%
Diabetes	<≥126 mg/dL	≥6.5%

Diabetes rarely exists in isolation. Insulin resistance, visceral adiposity, hypertension, and abnormal lipid patterns (specifically low HDL and elevated triglycerides) commonly cluster together. This state, frequently termed cardiometabolic disease, systematically degrades blood vessels through several overlapping frontlines:

• Vascular Inflammation: It fosters a chronic, pro-inflammatory environment that accelerates plaque instability.
• Particle Modification: It directly drives the accumulation of highly atherogenic, small, dense LDL particles.
• Endothelial Dysfunction: It impairs the single-cell arterial lining via multiple chemical pathways.

A framing that reflects the interconnected biology more accurately than treating each element as a separate condition.

---

Smoking: Immediate and Cumulative Vascular Injury

Smoking substantially increases cardiovascular risk through multiple simultaneous mechanisms: oxidative stress, endothelial dysfunction, platelet activation, increased clotting tendency, reduced HDL, and accelerated atherosclerosis throughout the vascular tree.[4] The cardiovascular consequences of smoking are not confined to lung cancer and emphysema — they operate through the same endothelial injury pathways that all other cardiovascular risk factors use, compounding the damage from any coexisting conditions.

Cessation reduces cardiovascular risk substantially, and the benefits begin earlier than most patients expect. Within months of stopping, endothelial function begins to improve. Over years of abstinence, cardiovascular risk progressively declines toward that of never-smokers, though the timeline depends on duration and intensity of prior exposure.[19]

---

Obesity, Physical Inactivity, and Sleep Apnea

Obesity — particularly visceral adiposity, the fat stored within and around the abdominal organs rather than subcutaneous fat — drives cardiovascular risk through specific metabolic mechanisms: insulin resistance, dyslipidaemia (abnormal blood lipid patterns, typically elevated triglycerides and reduced HDL cholesterol), elevated blood pressure, and chronic low-grade inflammation that affects plaque stability. These mechanisms explain most of obesity’s cardiovascular effect; excess weight is often best understood as a marker for the underlying metabolic dysfunction it produces.[20]

Physical inactivity independently increases cardiovascular risk even at the same body weight. Regular physical activity improves insulin sensitivity, raises HDL cholesterol, modestly lowers blood pressure, and reduces systemic inflammation — benefits that occur partly independent of any change in weight.[21] The combination of metabolic health and physical fitness matters. What is sometimes called “metabolically healthy obesity” may carry lower short-term measured risk, but metabolic complications commonly develop over time, and the degree of metabolic protection conferred by fitness in the setting of obesity has limits.

Obstructive sleep apnea is closely linked to obesity but exerts cardiovascular effects that extend beyond its association with weight. Through repetitive nocturnal hypoxia, sympathetic activation, and oxidative stress, sleep apnea independently contributes to hypertension, atrial fibrillation, coronary artery disease, and heart failure.[37] It is estimated to affect more than 40% of patients with established cardiovascular disease[37] and remains profoundly underdiagnosed. Many patients with sleep apnea are unaware they have it; a bed partner who witnesses apnoeas, loud snoring, or gasping during sleep, combined with excessive daytime fatigue and difficult-to-control hypertension, are common presentations. Treatment — most commonly continuous positive airway pressure — can reduce blood pressure and improve cardiovascular risk markers, particularly in patients with moderate to severe disease.

---

Metabolic Syndrome: Diagnostic Criteria for Metabolic Syndrome

Metabolic syndrome refers to the clinically recognised clustering of abdominal adiposity, dyslipidaemia, elevated blood pressure, and impaired glucose regulation. Under the standard diagnostic criteria for metabolic syndrome, it is defined as three or more of the following components present simultaneously:[36]

Component	Men	Women
Waist circumference	≥102 cm (40 in)	1≥88 cm (35 in)
Triglycerides	≥150 mg/dL	≥150 mg/dL
HDL cholesterol	<40 mg/dL	<50 mg/dL
Blood pressure	≥130/85 mmHg	≥130/85 mmHg
Fasting glucose	≥100 mg/dL	≥100 mg/dL

Different organisations use different waist circumference cutoffs across ethnic groups; the clinical value lies in recognising the pattern of insulin resistance and visceral adiposity, not in applying exact thresholds mechanically. Metabolic syndrome is common and increasing in prevalence — U.S. data suggest it affects a substantial proportion of adults, rising sharply with age.[22]

The significance of this pattern is that these components share underlying biology and damage blood vessels through complementary mechanisms simultaneously. Multiple borderline abnormalities in combination signal a metabolic problem more serious than any individual number suggests. A patient with blood pressure of 132/84, triglycerides of 165, HDL of 38, a waist circumference of 104 cm, and fasting glucose of 102 has five components, each of which might appear almost-normal in isolation. Together, they describe a clinical picture of sustained insulin resistance and visceral adiposity with ongoing vascular exposure on multiple biological fronts.

---

Why Borderline Numbers Go Unaddressed

One of the most consistent patterns in cardiovascular medicine is that mild abnormalities come to feel ordinary simply because they are so common. Several borderline markers frequently persist for years without triggering clinical alarm bells or obvious symptoms:

• Systolic blood pressure lingering continuously in the 130s.
• Fasting glucose values trickling slightly above 100 mg/dL.
• Visceral abdominal weight that accumulates slowly over decades.
• Total LDL particle levels settling just above optimal baselines. Because nothing hurts during this long development window, these metrics rarely feel dangerous to a patient, even while the underlying vascular biology is actively shifting.

This normalisation is physiologically understandable — the body compensates remarkably well during the long silent phase of coronary disease. But it means that the biological damage accumulates without producing the feedback that would naturally motivate change. Unlike an injury that produces immediate pain, vascular injury from chronic risk factor exposure is entirely invisible until something clinically significant occurs.

Clinically, one of the most common presentations is discovering substantial coronary artery calcium or three-vessel disease in a patient who had spent years with borderline values that never prompted concern at individual office visits. The history is almost always the same: numbers that were slightly off, noted and acknowledged, but never quite alarming enough to act on decisively. Those years represent cumulative arterial exposure that cannot be recovered.

---

Calculating Risk: Overcoming Limitations with the Prevent ASCVD Risk Calculator

Risk calculators estimate the probability of cardiovascular events over a defined period based on measured risk factors. The 2026 ACC/AHA Dyslipidemia Guideline formally retired the Pooled Cohort Equations and now recommends using the new prevent ASCVD risk calculator (the AHA’s PREVENT-ASCVD equations) for primary prevention risk assessment in adults aged 30–79 without known cardiovascular disease and with LDL-C between 70 and 189 mg/dL.[23,38] PREVENT estimates 10-year and 30-year cardiovascular risk. Importantly, PREVENT estimates are approximately 40–50% lower than Pooled Cohort Equation estimates for the same risk profile — meaning patients who were previously classified as intermediate risk may now fall into the borderline category with the same underlying biology.

Risk calculators estimate average risk for populations with similar characteristics. They cannot determine exactly what will happen to any individual patient — they cannot account for individual variation in plaque biology, subclinical disease already present, Lp(a) elevation (unless specifically included), chronic inflammatory conditions, or granular family history. These tools start a conversation about risk; they do not end it.

The 2026 guideline uses the following PREVENT-ASCVD risk thresholds to structure primary prevention decisions:[38]

10-Year PREVENT-ASCVD Risk	Risk Category	Clinical Framing
<3%	Low	Lifestyle optimisation; LLT generally not indicated
3–<5%	Borderline	≥LLT can be considered after clinician-patient discussion
5–<10%	Intermediate	LLT should be considered after clinician-patient discussion
≥10%	High	LLT is generally recommended alongside lifestyle

A 10-year risk of 5% means approximately a 1 in 20 chance of a major cardiovascular event — heart attack, stroke, or cardiovascular death — in the next decade. Whether that probability justifies preventive medication depends on individual values, the potential benefit and harm of treatment, and a conversation with a clinician. These calculators are designed for primary prevention in people without known cardiovascular disease. Patients who have already had a heart attack, stroke, or revascularisation procedure are in a different risk category entirely — secondary prevention — and these tools do not apply in the same way.

---

Additional Testing: Determining the Calcium Score of Coronary Artery

When calculated risk is intermediate, family history is concerning, or the clinical picture suggests more risk than conventional numbers reflect, additional testing can clarify whether risk has been under- or overestimated.

Evaluating the calcium score of coronary artery networks using a specialized CT scan allows clinicians to measure calcified plaque burden directly. Calcium accumulates in plaques that have been present long enough to mineralise — typically years — so a detectable calcium score is direct evidence that atherosclerosis is present, independent of what traditional risk factors suggest. The 2026 guideline gives CAC scoring a Class I (strongly recommended) indication for adults at intermediate PREVENT-ASCVD risk (5–<10%) and selected adults at borderline risk (3–<5%) when the decision about lipid-lowering therapy remains uncertain after a clinician-patient discussion.[38]

The following describes how CAC scores are interpreted under the 2026 guideline:[38]

CAC Score	Clinical Interpretation
0	No calcified plaque detected; may support deferral of statin therapy with repeat testing in 3–7 years, though does not exclude non-calcified plaque or higher-risk biology in diabetes, smokers, or those with strong family history
1–99	Atherosclerosis confirmed; supports initiation of lipid-lowering therapy
≥100 or ≥75th percentile for age/sex	Moderate-to-extensive plaque burden; initiation of therapy is indicated
≥300	Extensive plaque burden; supports intensive risk-factor management

A score of zero does not mean arteries are healthy. Younger individuals, patients with diabetes, smokers, and those with strong family history can still carry meaningful risk; clinical context overrides the score.[24] A score of 100 or above, or a score at or above the 75th percentile for age and sex — even if the absolute number appears modest — carries specific clinical weight in the 2026 framework and generally indicates therapy is warranted.[38]

High-sensitivity C-reactive protein (hs-CRP) measures systemic inflammation. As Article 1 explained, inflammation is central to plaque vulnerability. Elevated hs-CRP above 2 mg/L, particularly when persistent, is associated with increased cardiovascular risk independent of cholesterol levels, and may be clinically useful in intermediate-risk situations where inflammatory burden meaningfully shifts risk interpretation.[25]

---

Cardiovascular Risk Enhancers: Conditions Beyond Standard Calculators

Certain conditions, recognized clinically as cardiovascular risk enhancers, increase risk substantially beyond what standard equations estimate. Their presence often prompts clinicians to recalibrate how aggressively they pursue prevention:

Chronic kidney disease — reduced filtration (eGFR below 60; eGFR, or estimated glomerular filtration rate, measures how well the kidneys filter waste from blood, with normal being above 90 mL/min/1.73m²) or persistent albuminuria (protein in the urine, a sign of kidney damage affecting vascular integrity) — is associated with substantially elevated cardiovascular risk through a combination of inflammation, vascular calcification, abnormal lipid metabolism, and accelerated endothelial dysfunction.[26]

Chronic inflammatory diseases — including rheumatoid arthritis, psoriasis, lupus, and HIV — elevate cardiovascular risk beyond conventional risk factors through persistent inflammatory activity that promotes plaque instability and accelerates atherosclerosis.[27]

South Asian ancestry is associated with earlier and often more extensive coronary disease; contributing mechanisms likely include cardiometabolic factors and lipoprotein patterns that standard risk equations do not fully capture.[28]

Adverse pregnancy outcomes — including preeclampsia (a pregnancy complication characterised by high blood pressure and organ stress, typically in the second half of pregnancy), gestational diabetes, and preterm delivery — are associated with elevated long-term cardiovascular risk and may reveal persistent underlying vascular and metabolic susceptibility.[29]

Premature menopause, before age 40, removes oestrogen’s vascular-protective effects earlier in life, increasing cumulative exposure to cardiovascular risk factors over a longer subsequent lifespan.[30]

Obstructive sleep apnea, beyond its direct role in hypertension and metabolic dysfunction, is increasingly recognised as a cardiovascular risk amplifier particularly in patients with established coronary disease or those with multiple other risk factors.[37]

---

What the Evidence Shows About Reducing Risk

The following table summarises the major modifiable risk factors, their primary mechanism of vascular injury, and the evidence base for modification:[4,7,11,12,14,17,19,20,21,31,32]

Risk Factor	Primary Vascular Mechanism	Evidence for Modification
Elevated LDL cholesterol	Arterial wall lipid retention; plaque formation	Statins and other LDL-lowering therapies reduce cardiovascular events proportional to LDL reduction[14]
Hypertension	Endothelial mechanical stress; accelerated plaque development	Blood pressure treatment reduces stroke and coronary events across a wide range of baseline levels[31]
Diabetes / hyperglycaemia	Glycation of vascular proteins; endothelial dysfunction; pro-inflammatory environment	Glucose control reduces microvascular complications; GLP-1 receptor agonists and SGLT2 inhibitors reduce cardiovascular events and heart failure hospitalisations independently of glucose lowering in high-risk patients[17]
Smoking	Oxidative injury; endothelial dysfunction; platelet activation; accelerated atherosclerosis	Cessation reduces cardiovascular risk; benefits begin within months[19]
Obesity (visceral)	Insulin resistance; dyslipidaemia; hypertension; chronic inflammation	Weight reduction improves multiple cardiovascular risk factors simultaneously[20]
Physical inactivity	Reduced insulin sensitivity; lower HDL; elevated inflammation	Regular activity reduces cardiovascular risk independently of weight change[21]
Obstructive sleep apnea	Sympathetic activation; nocturnal hypertension; oxidative stress; endothelial dysfunction	Treatment reduces blood pressure and improves cardiovascular risk markers in moderate-severe disease[37]

---

What Patients Often Believe vs. What the Biology Does

These mismatches between common intuition and cardiovascular biology consistently shape how patients respond to risk factor management:

Common Assumption	What the Biology Actually Does
“My numbers are only slightly elevated.”	Small persistent abnormalities still produce cumulative arterial injury over decades — the total exposure matters more than any single reading.
“I feel fine, so my arteries must be fine.”	Plaque develops silently for years while the artery initially remodels outward to preserve blood flow. The absence of symptoms does not mean the absence of disease.
“My cholesterol isn’t that high.”	Cardiovascular risk depends on cumulative LDL exposure, particle burden, particle type, inflammation, metabolic health, and years of exposure — not cholesterol level at one visit.
“I’ll deal with it when it becomes a real problem.”	Earlier exposure reduction generally produces greater lifetime benefit because it limits plaque development during the decades when arteries are most biologically responsive to intervention.
“I exercise, so I should be protected.”	Exercise provides real and substantial cardiovascular benefit — but it cannot fully offset severe uncontrolled hypertension, smoking, or advanced metabolic disease operating through independent biological pathways.
“A normal stress test means my heart is healthy.”	Stress testing identifies flow-limiting obstruction. It does not evaluate plaque stability or detect the biologically unstable plaques responsible for many heart attacks.

---

What This Means

Risk factors are not pass-fail thresholds. They are measures of ongoing biological activity — the pressure on arterial walls, the cholesterol burden available to build plaque, the metabolic environment that determines how rapidly plaques develop and how stable they remain. Disease advances incrementally whether or not measurements have crossed the lines that prompt clinical action.

The principle that most changes how to engage with cardiovascular risk: it is not only today’s numbers, but how long arteries have been exposed to them. Modest differences in risk-factor exposure, sustained over years, become large differences in outcomes. Addressing borderline risk factors earlier prevents more plaque accumulation over a lifetime. Achieving the same numbers later stabilises disease that has already been developing. Both are valuable — but the biological leverage of earlier intervention is greater.

Risk reduction is not all-or-nothing, and it is never too late. Every improvement — in blood pressure, LDL, metabolic health, physical activity, or smoking exposure — reduces the ongoing biological burden on arterial walls. The cardiovascular system responds to reduced exposure, not only to perfect exposure. That principle applies at every age, at every stage of disease, and at every level of risk.

---

Key Terms

Apolipoprotein B (ApoB): A protein carried by each atherogenic lipoprotein particle; measuring ApoB estimates particle number, which often predicts cardiovascular risk more accurately than LDL cholesterol mass alone.[15]

HbA1c (glycated haemoglobin): A measure of the percentage of haemoglobin that has undergone glycation; approximates average blood glucose exposure over approximately three months, used to diagnose and monitor prediabetes and diabetes.

Lipoprotein(a) [Lp(a)]: An LDL-like particle carrying an additional protein that increases atherothrombotic potential; levels are largely genetic and do not respond meaningfully to standard lifestyle measures or most standard lipid therapies. The 2026 ACC/AHA Dyslipidemia Guideline recommends measuring Lp(a) at least once in all adults.[38]

Metabolic syndrome: A clinically recognised clustering of abdominal obesity, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose, linked by insulin resistance and visceral adiposity.[36]

PREVENT-ASCVD: Risk equations developed by the American Heart Association, now recommended by the 2026 ACC/AHA Dyslipidemia Guideline as the primary tool for cardiovascular risk assessment in primary prevention. Estimates 10-year and 30-year risk in adults aged 30–79; produces estimates approximately 40–50% lower than the prior Pooled Cohort Equations for the same patient profile.[23,38]

Risk enhancer: A condition — including chronic kidney disease, inflammatory disease, adverse pregnancy outcomes, sleep apnea, or strong family history — that increases cardiovascular risk beyond what standard risk calculators predict.[12,26–30]

Vascular age: The biological age of the arterial system based on cumulative risk factor exposure over time, which may differ meaningfully from chronological age.

---

References

1. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379–2393. https://doi.org/10.1016/j.jacc.2007.02.059
2. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551–561. https://doi.org/10.1161/01.ATV.15.5.551
3. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035–2042. https://doi.org/10.1001/jama.282.21.2035
4. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–1737. https://doi.org/10.1016/j.jacc.2003.12.047
5. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–2051. https://doi.org/10.1161/ATVBAHA.108.179705
6. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. https://doi.org/10.1016/S0140-6736(04)17018-9
7. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. https://doi.org/10.1161/01.CIR.97.18.1837
8. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–329. https://doi.org/10.1056/NEJMoa1012848
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–1811. https://doi.org/10.1056/NEJM199906103402306
10. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204–2211. https://doi.org/10.1001/jama.291.18.2204
11. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. https://doi.org/10.1016/S0140-6736(02)11911-8
12. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596–e646. https://doi.org/10.1161/CIR.0000000000000678
13. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. https://doi.org/10.1056/NEJMoa1511939
14. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5
15. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295. https://doi.org/10.1001/jamacardio.2019.3780
16. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. https://doi.org/10.1016/j.jacc.2016.11.042
17. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. https://doi.org/10.1016/S0140-6736(10)60484-9
18. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–811. https://doi.org/10.1056/NEJMoa0908359
19. Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015;350:h1551. https://doi.org/10.1136/bmj.h1551
20. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. https://doi.org/10.1161/CIR.0000000000000973
21. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116(19):2110–2118. https://doi.org/10.1161/CIRCULATIONAHA.107.729939
22. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323(24):2526–2528. https://doi.org/10.1001/jama.2020.4501
23. Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430–449. https://doi.org/10.1161/CIRCULATIONAHA.123.067626
24. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849–858. https://doi.org/10.1161/CIRCULATIONAHA.115.018524
25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–369. https://doi.org/10.1161/01.CIR.0000053730.47739.3C
26. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081. https://doi.org/10.1016/S0140-6736(10)60674-5
27. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482–489c. https://doi.org/10.1093/eurheartj/eht351
28. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments. Circulation. 2018;138(1):e1–e34. https://doi.org/10.1161/CIR.0000000000000580
29. Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women. Circulation. 2021;143(13):e902–e916. https://doi.org/10.1161/CIR.0000000000000961
30. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. https://doi.org/10.1001/jamacardio.2016.2415
31. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. https://doi.org/10.1016/S0140-6736(15)01225-8
32. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512
33. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–2639. https://doi.org/10.1016/j.jacc.2012.09.017
34. Nwabuo CC, Vasan RS, Tsao CW, et al. Long-term cumulative blood pressure in young adults and incident heart failure, coronary heart disease, stroke, and cardiovascular disease: the CARDIA study. Eur J Prev Cardiol. 2022;29(7):1047–1056. https://doi.org/10.1093/eurjpc/zwab036
35. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144
36. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement. Circulation. 2009;120(16):1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
37. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144:e56–e67. https://doi.org/10.1161/CIR.0000000000000988
38. Blumenthal RS, Morris PB, Bhatt DL, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. Epub ahead of print. https://doi.org/10.1016/j.jacc.2025.11.016